The effects of chronic gestational exposure to nicotine on the nucleus accumbens dopamine response to acute nicotine were determined during adolescence (postnatal day 29-36) in cross-fostered and non-cross-fostered Lewis rats. In both males and females, gestational nicotine exposure diminished the adolescent nucleus accumbens dopamine response to 0.07 mg/kg nicotine i.v. (p<0.05). However, dopamine responses to 0.105 mg/kg nicotine were unaffected by gestational nicotine treatment and were similar in both genders. Furthermore, in both female and male gestational nicotine and control groups, the dopamine response to nicotine (0.105) was the same as that observed to the lower dose of nicotine in gestational controls. Thus, in adolescent male and female Lewis rats, gestational nicotine exposure attenuated nucleus accumbens dopamine release to a maximally stimulative dose of nicotine. Unexpectedly, in female gestational controls cross-fostering per se reduced nucleus accumbens dopamine secretion to 0.07 mg/kg nicotine (p<0.05). These investigations suggest that gestational nicotine exposure could modify the acute reinforcing effects of nicotine in adolescent rats, while early postnatal stressors, (e.g. cross-fostering) may affect nicotine-induced reinforcement in female but not male adolescents. Less than ten percent of smokers initiate tobacco use as adults (Chassin et al., 1996; Dappen et al., 1996; USDHHS, 1989), yet animal models of nicotine treatment and self-administration focus, almost exclusively, on adult males. In the United States, the prevalence of cigarette use increases across genders until the age of 20 (USDHHS, 2001).
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darkroom lit with a red safe-light. Microdialysis probes were perfused at 1 µl/min with a solution of Kreb's Ringer Buffer (KRB: 147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl 2 , and 0.85 mM MgCl 2 , in polished water; 0.2 µm filter sterilized and degassed) containing 5 µM nomifensine. Nomifensine was added to the perfusate to ensure the detection of basal dopamine levels.
Microdialysis began 150 min after insertion of the probes through the guide cannulae; consecutive 15 min samples were collected into vials containing 1 µl of 5% perchloric acid. Three baseline samples were collected for analysis prior to an initial IV injection of either 0.07 mg/kg nicotine or 0.105 mg/kg nicotine in 100 µl of 0.9% sodium chloride over 70 sec. The dose of 0.07 mg/kg nicotine, defined as maximally stimulative (see Results), produced maximal dopamine secretion in the nucleus accumbens of adolescent non-cross-fostered control rats without adverse behavioral effects. In this treatment group, 0.105 mg/kg nicotine did not stimulate adverse behaviors nor did it induce a greater dopamine response than 0.07 mg/kg nicotine. However, higher doses were not used because they elicited adverse behavioral effects. Following the first injection of 0.07 mg/kg, nicotine, six samples were collected, and then a second identical injection was delivered and four additional samples were obtained. Following 0.105 mg/kg nicotine, four samples were collected to determine the peak response to a single injection at this dose. At the end of the experiments, the position of each probe was verified histologically. Only data from animals with probes located in the shell of the nucleus accumbens were utilized.
HPLC-electrochemical analysis: Chromatographic separation of dopamine was achieved with a 150 x 2 mm ODS C18 column (ESA) connected to an ESA model 580
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JPET Fast Forward. Published on November 10, 2003 as DOI: 10.1124 at ASPET Journals on October 2, 2017 jpet.aspetjournals.org Downloaded from HPLC pump. The mobile phase (0.5 ml/min) contained 50 mM sodium dihydrogen phosphate monohydrate, 2.0 mM decanesulfonic acid (DSA), 0.7 mM EDTA, 11% acetonitrile, and 11% methanol, pH 6.0. Samples (15 µl) were automatically injected by a CMA 200 refrigerated autosampler, and were analyzed by an ESA Coulochem II 5200A electrochemical detector with an ESA 5041 high sensitivity analytical cell and an ESA 5020 guard cell (ESA, Inc., Chelmsford, MA). Electrochemical detection was performed at 220 mV and 10 nA, with the guard cell at 350 mV. Under these conditions, the limit of detection for dopamine was 100 fg per injection.
Analysis of nucleus accumbens dopamine content: Twenty-eight day old female Lewis rats, treated during gestation with nicotine (n=8) or vehicle (n=8), were used to obtain nucleus accumbens tissue samples for dopamine and protein content. The methods used were similar to those described previously (Bergstrom et al., 2001) . Briefly, brains were removed and placed in cold saline. The brains were then aligned on a tissue slicer (Stoelting, Wood Dale, IL), using the anterior optic chiasm and middle meningeal arteries as reference points, shifted 6 mm forward, and sliced into 1.5 mm sections with a razor blade. The nucleus accumbens tissue was microdissected, using a punch with an internal diameter of 2 mm, placed in a vial containing 500 µl of perchloric acid, homogenized, and then centrifuged. Dopamine levels in the supernatants were measured by HPLC with electrochemical detection, as described above. The precipitates were dissolved in NaOH and assayed for protein content, using a BCA kit (Pierce, Rockford, IL). nicotine attenuated the dopamine response; peak dopamine levels were 35±6% above baseline in the non-cross-fostered gestational nicotine cohort (see Table 1 In order to identify the main effects and interactions of treatments, basal dopamine levels were compared between all treatment groups that received acute injections of nicotine (see Table 2 for a summary of basal dopamine values). In female offspring that had received gestational nicotine, baseline dopamine levels were unaffected (1.6±0.2 pg/10 µl vs. 1.5±0.2 pg/10 µl for gestational nicotine vs. control, This article has not been copyedited and formatted. The final version may differ from this version. non-cross-fostered offspring because (i) cross-fostering did not interact with gestational treatment on basal dopamine levels or nicotine-induced dopamine secretion, and (ii) the primary purpose of these investigations was to determine the effects of gestational exposure to nicotine. In summary, gestational nicotine had no effect on baseline extracellular nucleus accembens dopamine levels or on total dopamine content.
In adolescent females, the absence of an interaction between gestational nicotine treatment and cross-fostering (figure 2) makes it unlikely that cross-fostering would alter the peak response to a higher dose of acute nicotine. Therefore, further experiments evaluated the acute stimulation of dopamine release by a higher dose of nicotine in noncross-fostered offspring exposed to gestational nicotine. Figure 3 demonstrates nucleus accumbens dopamine release in response to an acute injection of 0.105 mg/kg nicotine. In contrast to nicotine 0.07 mg/kg, there was no difference in dopamine release between female offspring that had received gestational control vs. gestational nicotine. In these groups, dopamine release increased by 63±9% and 82±10% above baseline levels, respectively. Moreover, these dopamine responses to 0.105 mg/kg nicotine were no This article has not been copyedited and formatted. The final version may differ from this version. fig. 2 ). Thus, a higher dose of nicotine (0.105 mg/kg) is required to stimulate maximal nucleus accumbens dopamine release in female offspring that were exposed to nicotine during gestation. The dopamine response to this dose of nicotine was not accompanied by adverse behavioral responses in females, but higher doses were and, therefore, could not be tested. To evaluate the effects of a higher dose of nicotine on dopamine release in male offspring exposed to prenatal nicotine, experiments were again focused on non-crossfostered offspring, since no interaction between gestational nicotine and cross-fostering was demonstrated. 
